JAZZ

Jazz Pharmaceuticals

$211.97

-0.84% Oct 21 close

Health CareS&P 400 Compare

1M 3M 6M 1Y 2Y

JAZZSPY

+1.1%

-12.2%

-15.4%

+4.7%

YTD

+24.7%

+54.2%

Live chart

Loading live chart…

What they do

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH). It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC).

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

Momentum

84th percentile in sector

A-

12-1 return: +68.2%
Percentile within its GICS sector across the S&P 1500.

Growth

73rd percentile in sector

B+

Revenue growth (YoY): +15.5%
Percentile within its GICS sector across the S&P 1500.

Value

91st percentile in sector

Forward E/P: 12.4% · EBITDA/EV: 12.2%
Percentile within its GICS sector across the S&P 1500.

Profitability

80th percentile in sector

A-

Profit margin: +20.4% · Return on equity: +22.1%
Percentile within its GICS sector across the S&P 1500.

Revisions

Not enough data yet

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Held by 1 of 5 live models: New Highs Growth.

New Highs Growth

4.0% of the book

Held Quality Growth

Outside this model's universe or screens

Momentum Top 15

Outside this model's universe or screens

Momentum Blend

Not in the current book

Coteau Long Book

Not in the current book

Why it's in the New Highs Growth

Qualified on Pharma, -12% from 52-week high, held: still within 25% of its high, 12-1 momentum +94%.

What would knock it out: Drops out if it falls outside the top 25 at the next rebalance (Oct 30). In the latest preview (2026-10-20) it is outside the top 25.

News

More news

No recent headlines.

Key stats

52-week range$131.16 – $261.62

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Leans undervalued

Model read-out from the numbers below, not advice. Score +2 (DCF counts double).

▲DCF (base case)above the price by 85%

•Piotroski F-score5/9

•Net debt / EBITDA2.9x

Discounted cash flow

Bear

$234

+10%

growth 0% · disc. 10.2% · term. 2.0%

Base

$393

+85%

growth 5% · disc. 9.2% · term. 2.5%

Bull

$610

+188%

growth 8% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Not enough data to run a reverse DCF.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9×

–

Forward P/E

sector median 17.6×

–

EV / EBITDA

sector median 15.8×

–

Price / sales

sector median 3.1×

–

Price / book

sector median 3.5×

–

FCF yield

sector median 4.1%

–

Quality & financial health

Gross margin

–

Operating margin

19.5%

FCF margin

34.6%

Net margin

20.4%

Return on equity

19.6%

Return on invested capital

11.9%

Net debt / EBITDA

2.9×

Current ratio

1.8×

Interest cover

27.3×

Cash conversion (OCF/NI)

1.8×

Piotroski F-score 5/9 · last two fiscal years

✗ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FY	Revenue	Net income	Free cash flow
2025	$4.3B	$-356.1M	$1.3B
2024	$4.1B	$560.1M	$1.4B
2023	$3.8B	$414.8M	$1.1B
2022	$3.7B	$-224.1M	$1.2B
2021	$3.1B	$-329.7M	$750.9M
2020	$2.4B	$238.6M	$884.6M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +5.3%.

Earnings

Next report: 2026-11-02 · during market · EPS est 2.56

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-03	6.18	5.71	-7.5%
2026-05-05	4.66	6.34	+36.2%
2026-02-24	6.51	6.64	+2.0%
2025-11-05	5.85	8.13	+39.0%
2025-08-05	-6.25	-8.25	-32.1%
2025-05-06	4.66	1.68	-63.9%
2025-02-25	5.81	6.60	+13.6%
2024-11-06	5.50	6.61	+20.2%

Insider trades

Gala Renee D

Director, President & CEO · 2026-10-06

SELL
$472.8K

Cozadd Bruce C

Director · 2026-10-01

SELL
$1.4M

Patil Neena M

EVP & Chief Legal Officer · 2026-09-10

SELL
$289.1K

Gala Renee D

President & CEO · 2026-09-08

SELL
$486.1K

Cozadd Bruce C

Director · 2026-09-01

SELL
$1.5M

Iannone Robert